Document is current

Article History

First Online: 23 February 2024

Declarations

:

: Sagar V. Mehta has received compensation from Novo Nordisk for participation on an Emerging Thought Leader Steering Committee. Shelby Sullivan has received research Funding from Allurion Technologies (ongoing), Aspire Bariatrics (ended 2021), Obalon Therapeutics (ended 2021) and has received compensation for service as a consultant from Allurion Technologies (ended 2022), USGI Medical (ended 2018), GI Dynamics (ended 2018), Obalon Therapeutics (ended 2019), Nitinotes Surgical (ended 2021), Phenomix Sciences (ended 2020), Elira (ended 2021), Chair of the Board for the Association of Bariatric Endoscopy (ended 2022), Biolinq, Bariatek, Endo Tools Therapeutics, Pentax. Fernanda Pessorrusso has no conflicts of interest to report.

: All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki Declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).